MedTest Dx FDA-approved quantitative test for G6PD

written by CAP TODAY
May 19, 2020

May 2020—MedTest Dx announced the availability of its Pointe Scientific–branded assay for the highly sensitive quantification of G6PD in whole blood.

Understanding the G6PD status of COVID-19 patients is essential to prevent severe adverse reactions to chloroquine and hydroxychloroquine, two antimalarial drugs that are being investigated for use as treatment for the novel coronavirus. G6PD deficiency is the most common enzymatic blood disorder, affecting about 400 million people worldwide.

Manufacturers are required to include a contraindication regarding administration of chloroquine or hydroxychloroquine to those with a G6PD deficiency. Most patients with this disorder do not know they have it, which makes testing prior to administration critical, the company said in a press statement. MedTest Dx's G6PD assay is designed to run concurrently with standard diagnostic tests, such as hemoglobin determination, on a range of analyzers. On-board lysis provides results in minutes.

MedTest Dx, 800-445-9853